Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis

Απλή σελίδα τεκμηρίου
dc.contributor.authorZintzaras, E.en
dc.contributor.authorKitsios, G. D.en
dc.contributor.authorPapathanasiou, A. A.en
dc.contributor.authorKonitsiotis, S.en
dc.contributor.authorMiligkos, M.en
dc.contributor.authorRodopoulou, P.en
dc.contributor.authorHadjigeorgiou, G. M.en
dc.date.accessioned2015-11-24T18:55:04Z
dc.date.available2015-11-24T18:55:04Z
dc.identifier.issn1879-114X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18803
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectDopamine Agonists/administration & dosage/adverse effects/*therapeutic useen
dc.subjectEvidence-Based Medicineen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPlacebo Effecten
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectRestless Legs Syndrome/diagnosis/*drug therapyen
dc.subjectRisk Assessmenten
dc.subjectTreatment Outcomeen
dc.titleRandomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysisen
heal.abstractBACKGROUND: The use of dopamine agonists (DAs) for the treatment of restless legs syndrome (RLS) has been assessed in numerous randomized clinical trials (RCTs). OBJECTIVES: The aims of this study were to assess the reporting quality of published RCTs according to the Consolidated Standards of Reporting Trials (CONSORT) statement and to synthesize the study results in terms of efficacy and tolerability to inform the clinical management of RLS. METHODS: PubMed and Cochrane Controlled Trials Register were searched for English-language RCTs that assessed the effects of DAs in RLS. Quality of reporting was measured using the proportion of 17 CONSORT checklist items included in each study. The 2 primary outcomes were pooled mean change from baseline in International RLS (IRLS) Study Group rating scale score (Deltamu) (95% CI) and relative risk (RR) (95% CI) of response based on the Clinical Global Impression-Improvement (CGI-I) scale score. The pooled proportions of adverse events (PAEs) (95% CI) were also estimated. RESULTS: Eighteen RCTs (N = 2848 patients) were included. Two of the 17 CONSORT checklist items were reported in 7 studies (39%) and 9 of the 17 items were reported in all 18 studies (100%). The differences in the IRLS scores and RR for CGI-I were significantly greater with pramipexole, ropinirole, rotigotine, and cabergoline compared with placebo. Results for heterogeneity were nonsignificant. The difference in Deltamu (95% CI) was significant with pramipexole (-6.63 [-9.15 to -4.10]) versus ropinirole (-3.64 [-4.76 to 2.51]) (P = 0.04). The difference between pramipexole and rotigotine was nonsignificant. The pooled PAEs (95% CI) for pramipexole, ropinirole, and rotigotine were 4.8% (2.0% to 8.7%), 10.2% (2.6% to 22.1%), and 7.6% (1.3% to 18.5%), respectively. In the trial of sumanirole, the PAE value was 2% (0% to 5.4%). CONCLUSION: Based on the findings from the meta-analysis, DAs were significantly more efficacious in the treatment of RLS compared with placebo.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.clinthera.2010.01.028-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20206780-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0149291810000299/1-s2.0-S0149291810000299-main.pdf?_tid=ca4e18cea987e78705fe5e9e8a915db9&acdnat=1332840526_a4a3ab23382bfe52570bf290a428a19e-
heal.journalNameClin Theren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2010-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ